康泰生物
(300601)
| 流通市值：152.35亿 | | | 总市值：188.98亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,123,109,043.92 | 216,201,021.06 | 219,937,690.38 | 432,840,378.47 |
| 交易性金融资产 | 527,400,900 | 30,058,300 | - | 0 |
| 应收票据及应收账款 | 2,826,265,882.01 | 2,913,497,715.05 | 2,863,081,707.32 | 2,787,045,936.42 |
| 其中：应收票据 | - | - | 8,817,001.01 | - |
| 应收账款 | 2,826,265,882.01 | 2,913,497,715.05 | 2,854,264,706.31 | 2,787,045,936.42 |
| 应收款项融资 | - | - | - | 0 |
| 预付款项 | 27,810,938.82 | 17,238,756.21 | 24,177,808.47 | 26,578,453.93 |
| 其他应收款合计 | 7,279,819.78 | 9,665,759.08 | 8,580,322.35 | 10,536,156.67 |
| 存货 | 630,237,169.62 | 679,581,268.84 | 726,163,704.93 | 782,767,957.21 |
| 其他流动资产 | 1,070,462,276.84 | 2,224,776,127.33 | 2,387,591,312 | 2,202,520,055.69 |
| 流动资产合计 | 6,212,566,030.99 | 6,091,018,947.57 | 6,229,532,545.45 | 6,242,288,938.39 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 1 | 1 | - | 0 |
| 投资性房地产 | 766,527,224.52 | 773,040,611.91 | 783,356,053.57 | 787,547,166.28 |
| 固定资产 | 4,230,960,200.72 | 4,132,994,765.56 | 4,193,402,763.11 | 4,235,306,504.99 |
| 在建工程 | 783,786,973.08 | 959,925,440.54 | 962,817,334.98 | 990,283,518.03 |
| 无形资产 | 475,609,881.31 | 415,053,694.91 | 427,583,964.18 | 436,663,032.83 |
| 开发支出 | 75,278,108.3 | 134,453,102.09 | 115,849,555.45 | 97,794,434.53 |
| 长期待摊费用 | 142,935,399.31 | 148,011,021.76 | 159,226,115.56 | 170,461,150.91 |
| 递延所得税资产 | 744,190,540.51 | 732,933,317.78 | 693,042,229.68 | 697,626,350.41 |
| 其他非流动资产 | 702,472,160.54 | 741,493,899.77 | 690,117,086.56 | 905,743,398.96 |
| 非流动资产合计 | 7,921,760,489.29 | 8,037,905,855.32 | 8,025,395,103.09 | 8,321,425,556.94 |
| 资产总计 | 14,134,326,520.28 | 14,128,924,802.89 | 14,254,927,648.54 | 14,563,714,495.33 |
| 流动负债: | | | | |
| 短期借款 | 14,400,000 | 39,900,000 | 35,606,312.5 | 34,102,910.54 |
| 应付票据及应付账款 | 709,596,042.29 | 704,585,457.7 | 709,837,080.52 | 847,825,622.04 |
| 其中：应付票据 | 154,280,925.92 | 142,496,467.9 | 152,362,517.69 | 186,780,333.79 |
| 应付账款 | 555,315,116.37 | 562,088,989.8 | 557,474,562.83 | 661,045,288.25 |
| 预收款项 | 8,777,882.48 | 3,257,617.78 | 733,285.43 | 858,863.08 |
| 合同负债 | 33,466,178.19 | 18,159,321.93 | 19,347,470.26 | 18,421,267.86 |
| 应付职工薪酬 | 30,177,978.31 | 31,542,317.48 | 39,662,035.18 | 58,882,396.1 |
| 应交税费 | 17,133,230.38 | 18,297,706.41 | 14,580,910.1 | 22,289,407.63 |
| 其他应付款合计 | 1,478,248,351.51 | 1,442,636,970.87 | 1,395,966,085 | 1,461,258,486.9 |
| 一年内到期的非流动负债 | 7,590,687.46 | 28,173,926.67 | 111,168,017.6 | 202,954,572.59 |
| 其他流动负债 | 1,040,217.45 | 530,369.37 | 585,017.04 | 552,638.05 |
| 流动负债合计 | 2,300,430,568.07 | 2,287,083,688.21 | 2,327,486,213.63 | 2,647,146,164.79 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 0 |
| 应付债券 | 1,848,892,938.38 | 1,828,502,013.3 | 1,807,229,504.05 | 1,786,479,371.34 |
| 预计负债 | 109,174,933.64 | 143,120,378.89 | 151,281,291.43 | 186,717,135.91 |
| 递延收益 | 234,111,073.32 | 240,094,075.8 | 251,052,687.98 | 247,824,792.28 |
| 递延所得税负债 | 31,201,827.64 | 31,201,827.64 | 34,483,765.22 | 34,521,682 |
| 非流动负债合计 | 2,223,380,772.98 | 2,242,918,295.63 | 2,244,047,248.68 | 2,255,542,981.53 |
| 负债合计 | 4,523,811,341.05 | 4,530,001,983.84 | 4,571,533,462.31 | 4,902,689,146.32 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,116,929,111 | 1,116,928,537 | 1,116,927,887 | 1,116,927,737 |
| 其他权益工具 | 511,039,690.65 | 511,042,017.06 | 511,044,650.24 | 511,045,417.19 |
| 资本公积 | 5,511,654,387.54 | 5,511,644,315.26 | 5,510,766,852.12 | 5,510,725,626.71 |
| 其他综合收益 | -184,312.66 | -186,905.8 | -147,820.98 | -90,939.67 |
| 盈余公积 | 347,128,374.64 | 347,128,374.64 | 347,128,374.64 | 347,128,374.64 |
| 未分配利润 | 2,124,021,818.17 | 2,112,396,887.74 | 2,197,821,795.31 | 2,175,387,706.75 |
| 归属于母公司股东权益合计 | 9,610,589,069.34 | 9,598,953,225.9 | 9,683,541,738.33 | 9,661,123,922.62 |
| 少数股东权益 | -73,890.11 | -30,406.85 | -147,552.1 | -98,573.61 |
| 股东权益合计 | 9,610,515,179.23 | 9,598,922,819.05 | 9,683,394,186.23 | 9,661,025,349.01 |
| 负债和股东权益合计 | 14,134,326,520.28 | 14,128,924,802.89 | 14,254,927,648.54 | 14,563,714,495.33 |
| 公告日期 | 2025-10-28 | 2025-08-22 | 2025-04-21 | 2025-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |